{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:58Z","timestamp":1788052498453,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119203","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:06:45Z","timestamp":1785510405000},"page":"119203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies"],"prefix":"10.1016","volume":"318","author":[{"given":"Ru","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4908-0189","authenticated-orcid":false,"given":"Yiqi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-495X","authenticated-orcid":false,"given":"Xiaolu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-3693","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119203_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119203_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119203_bib3","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/ijms25042208","article-title":"Bruton's tyrosine kinase inhibitors: recent updates","volume":"25","author":"Fares","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119203_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13543776.2019.1594777","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)","volume":"29","author":"Feng","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119203_bib5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/molecules28052400","article-title":"Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119203_bib6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/13543776.2025.2554638","article-title":"Bruton's tyrosine kinase (BTK) inhibitors: an updated patent review (2019\u20132024)","volume":"35","author":"Cui","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119203_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119203_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","article-title":"Acalabrutinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119203_bib9","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119203_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119203_bib12","first-page":"336","article-title":"Managing toxicities of bruton tyrosine kinase inhibitors","author":"Lipsky","year":"2020","journal-title":"Hematology 2020"},{"key":"10.1016\/j.ejmech.2026.119203_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119203_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","article-title":"Tirabrutinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119203_bib15","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2025-3896","article-title":"Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"146","author":"Song","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119203_bib16","first-page":"570","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC (J. Am. Coll. Cardiol.): Cardio-Oncology"},{"key":"10.1016\/j.ejmech.2026.119203_bib17","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1021\/acs.jmedchem.2c00030","article-title":"Medicinal chemistry strategies for the development of bruton's tyrosine kinase inhibitors against resistance","volume":"2022","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib18","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.3390\/cancers16203434","article-title":"Advances in targeted therapy: addressing resistance to BTK inhibition in B-Cell lymphoid malignancies","volume":"16","author":"Bravo-Gonzalez","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119203_bib19","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New means and challenges in the targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119203_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non\u2010hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2026.119203_bib21","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119203_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114232","article-title":"Recent development of BTK-based dual inhibitors in the treatment of cancers","volume":"233","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119203_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","article-title":"Pirtobrutinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119203_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO-25-02477","article-title":"Pirtobrutinib versus ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"44","author":"Woyach","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119203_bib27","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/cancers15051504","article-title":"Next generation BTK inhibitors in CLL: evolving challenges and new opportunities","volume":"15","author":"Frustaci","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119203_bib28","first-page":"TPS7088","article-title":"BELLWAVE-011: phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"42","author":"Tadmor","year":"2024","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2026.119203_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","article-title":"Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia","volume":"15","author":"Muhowski","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119203_bib30","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood-2025-3889","article-title":"Phase 1\/2 studies of DZD8586 in CLL\/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders \u2013 extended follow-up report","volume":"146","author":"Zhou","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119203_bib31","series-title":"Ltd., A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","year":"2026"},{"key":"10.1016\/j.ejmech.2026.119203_bib32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the bruton's tyrosine kinase inhibitor fenebrutinib (GDC\u20100853) in systemic lupus erythematosus: results of a phase II, randomized, double\u2010blind, placebo\u2010controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejmech.2026.119203_bib33","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119203_bib34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2026.119203_bib35","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1021\/acs.jmedchem.5c00439","article-title":"Design, synthesis, and biological evaluation of pyrrolo[1,2- a ]quinoxalin-4(5 H)-one derivatives as potent and orally available noncovalent bruton's tyrosine kinase (BTK) inhibitors","volume":"68","author":"Tian","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib36","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/acs.jmedchem.5c02785","article-title":"Strategic use of benzylic alcohols reveals cryptic hydrogen-bonding interactions: discovery of HBC-12551 as a potent noncovalent bruton's tyrosine kinase inhibitor","volume":"69","author":"Liu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114913","article-title":"Development of novel hydrazidoarylaminopyrimidine-based BTK\/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects","volume":"245","author":"Ran","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12876-021-01982-4","article-title":"Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.119203_bib39","article-title":"Phase I trial to evaluate the tolerance, pharmacokinetics and efficacy of the broad-spectrum ErbB family inhibitor larotinib mesylate in patients with advanced solid tumors","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119203_bib40","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1021\/acs.jmedchem.1c02208","article-title":"Discovery of pteridine-7(8 H)-one derivatives as potent and selective inhibitors of bruton's tyrosine kinase (BTK)","volume":"65","author":"Dou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105541","article-title":"Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent bruton's tyrosine kinase (BTK) inhibitors","volume":"119","author":"Dou","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104385","article-title":"Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML","volume":"106","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119203_bib43","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2013-06-511154","article-title":"Identification of bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia","volume":"123","author":"Rushworth","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119203_bib44","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.apsb.2025.07.003","article-title":"USP20 as a super-enhancer-regulated gene drives T-ALL progression via HIF1A deubiquitination","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119203_bib45","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.7150\/ijbs.122898","article-title":"USP20, a super-enhancer regulated gene, promotes acute myeloid leukemia progression through CTNNB1 deubiquitination","volume":"22","author":"Cheng","year":"2026","journal-title":"Int. J. Biol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:19:09Z","timestamp":1788049149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"alternative-id":["S0223523426006483"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119203","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119203"}}